News

Brookfield Corporation Announces New Fixed Dividend Rate Details

Brookfield Corporation Announces New Fixed Dividend Rate Details

Brookfield Corporation Sets New Dividend Rates for Series 42 Shares

BROOKFIELD, NEWS – Brookfield Corporation (NYSE: BN, TSX: BN) recently shared important news regarding its Cumulative Class A Preference Shares, Series 42. They have announced a fixed dividend rate that will be effective for the next five years, beginning on July 1, 2025, and concluding on June 30, 2030.

Fixed Quarterly Dividend Details

The announced fixed quarterly dividends for the Series 42 Shares will be set at an attractive annual rate of 5.658%. This translates to a payment of approximately $0.353625 for each share on a quarterly basis, providing a steady return to investors during this period.

Options for Shareholders

An exciting option for current holders of the Series 42 Shares is available. They have the choice to convert their shares into Cumulative Class A Preference Shares, Series 43, at a one-for-one conversion rate. This option must be executed by no later than 5:00 p.m. Toronto time on June 16, 2025. The Series 43 Shares will offer a floating quarterly dividend rate calculated as 2.84% over the yield on three-month Government of Canada treasury bills.

Understanding the Dividend Rate for Series 43 Shares

For those contemplating the conversion, the projected quarterly dividend rate for the Series 43 Shares for July to September 2025 is anticipated to be about 1.38227%, equating to an annualized rate of 5.484%. This dividend would come in at roughly $0.3455675 per share, due for distribution on September 30, 2025.

Conversion Conditions

It is important to note that shareholders are not obligated to convert their Series 42 Shares. However, there are stipulations regarding the conversion based on the number of outstanding shares. Should Brookfield determine that the remaining Series 42 Shares are fewer than 1,000,000 after June 30, 2025, an automatic conversion will occur.

Stock Exchange Listings

The Toronto Stock Exchange (TSX) has conditionally approved the listing of the Series 43 Shares, contingent upon Brookfield meeting all the necessary listing requirements, which adds further confidence for investors looking at these shares.

About Brookfield Corporation

Brookfield Corporation is a prominent global investment firm, dedicated to creating long-term wealth for a diverse range of institutions and individual investors. They operate across three main business sectors: Alternative Asset Management, Wealth Solutions, and Operating Businesses, which span renewable energy, infrastructure, and real estate, among other fields.

The firm boasts a strong history of generating over 15% annualized returns for its shareholders for more than three decades, owing to its exceptional investment acumen and operational expertise. With a conservatively managed balance sheet and extensive operational capabilities, Brookfield consistently identifies unique investment opportunities.

Central to their enduring success is the Brookfield Ecosystem, which promotes collaboration among its various divisions, creating a robust framework for growth. Brookfield Corporation trades openly on major stock exchanges in the United States and Canada, under the ticker symbols NYSE: BN and TSX: BN.

For further inquiries or information, interested parties can visit Brookfield's official website or reach out directly to their media or investor relations teams.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ON1 Photo RAW 2027: New AI Tools, Better Processing

Updated Category News Views 50

Aiming for the Photography Crown ON1 isn't just tinkering on the fringes with their new Photo RAW 2027 release—they're diving headfirst into the deep end, aiming to outdo giants in the RAW processing world. I've seen my share of software updates that don't move the needle, but this one's packed to the gills with updates that photographers have been clamoring for. What's...

Continue Reading
China's Innovation Surge: Game Changer for Global Markets

Updated Category News Views 235

The Bold Shift in China's Economic Landscape Well, here's the scoop: China isn't just the world's assembly line anymore; it's gearing up to be a top-tier innovation hub. On the surface, might seem like another geopolitical spiel, but dig a little and you'll find it's a serious shake-up for global markets. We're talking about more than just products rolling out of...

Continue Reading
Jeep Wrangler Scrambler SRT: A Bold Off-Road Rebirth

Updated Category News Views 0

A New Legend in the Making Who would've thought we'd see the day when an SRT badge graced a Jeep Wrangler with such audacity? This ain't your typical Wrangler—they’ve slapped a bit of that CJ-8 throwback swagger, and given it the full-on SRT treatment. It's a mad machine, barreling into the future with one foot firmly planted in its legendary past. You ask any...

Continue Reading
Florida Homebuyers: Navigating Flood Zone Risks Smartly

Updated Category News Views 92

Florida Properties: The Buried Risk in Flood Zones If you’re dreaming of palm trees and sandy beaches, don't let flood zones turn that dream into a nightmare. It’s not all sunshine and rainbows when it comes to buying real estate in Florida, as it turns out—flood zones are lurking, and the devil's in the details. Understanding FEMA Flood Maps First off, these FEMA...

Continue Reading
ACA 2027 Enrollment: New Rules Aim to Simplify Coverage

Updated Category News Views 61

Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...

Continue Reading
Beyon Expands Green Data Centres to Three Facilities

Updated Category News Views 37

Blazing Solar Trails in the Digital Landscape Lend an ear, folks, because Beyon's latest leap in the world of renewable energy isn't just another 'look how green we are' maneuver. Announced during Gateway Gulf 2026, this venture is all about serious numbers and even more serious energy chops. Beyon's on course to power a third data center entirely through solar energy,...

Continue Reading
Lazard Closes Deal with Campbell, Launches Lazard CL

Updated Category News Views 59

Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...

Continue Reading
Xylitol: A Game Changer in Kids' Oral Care Battle

Updated Category News Views 91

Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...

Continue Reading
Military Medical Minds to Converge at MTEC Event in 2027

Updated Category News Views 72

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Continue Reading
Sirolimus-Coated Balloon Shows Promise in TRANSFORM II

Updated Category News Views 96

Breaking Down the TRANSFORM II Trial Innovation never rests, folks, especially when it comes to treating coronary artery disease. Right on cue, the TRANSFORM II trial's results have hit the airwaves, marking a significant milestone with its implant-free MagicTouch Sirolimus-Coated Balloon (SCB) strategy. Getting the Lay of the Land This wasn't just some backyard...

Continue Reading

Top 5 Most Recently Viewed Articles

ATYR Stock Investors: Important Class Action Update

Updated Category News Views 139

Key Information for ATYR Pharma Shareholders ATYR Pharma, Inc. has recently faced significant challenges that have caught the attention of its shareholders. Investors who have purchased shares of ATYR during the specified class period are encouraged to stay informed about the ongoing legal developments. Engaging with The Gross Law Firm can provide shareholders with the...

Continue Reading
Zymeworks Stock Target Steady After Positive Trial Results

Updated Category News Views 89

Zymeworks Keeps Stock Rating Steady After ESMO 2024 Results Zymeworks Inc. (NASDAQ: ZYME) has maintained its stock rating and price target after revealing encouraging results from its recent cancer treatment clinical trials at a significant medical conference. The ratings firm H.C. Wainwright has reiterated a Neutral rating and set a price target of $10.00 per share...

Continue Reading
Exploring New Opportunities in Convertible Bonds with BMAX ETF

Updated Category News Views 253

Introduction to the New ETF A recently introduced exchange-traded fund (ETF), known as the REX Bitcoin Corporate Treasury Convertible Bond ETF (BMAX), is gaining attention for its focus on convertible bonds from companies that have Bitcoin included in their financial strategies. This ETF began trading recently and represents a growing trend in the investment landscape....

Continue Reading
iBio Secures Strategic Investments to Propel Biotech Advancements

Updated Category News Views 140

iBio's Strategic Investment Announcement iBio, Inc. (NYSE: IBIO), a pioneer in AI-driven antibody immunotherapies, has made an impactful stride in its mission, announcing the successful closure of a private investment offering totaling over $650,000 from its Board of Directors and corporate officers. This investment is a significant vote of confidence in iBio's strategy...

Continue Reading
Simulmedia Welcomes Jonathan Steuer as Chief Scientist

Updated Category News Views 111

Simulmedia Appoints Jonathan Steuer as Chief Scientist Simulmedia, a leader in cross-channel TV and connected TV (CTV) advertising, is thrilled to announce a significant addition to its executive team. Jonathan Steuer, a prominent figure in media research and data science, has been appointed as the Chief Scientist. With a remarkable background as a scientist and...

Continue Reading